Once they try to get off, the weight comes back.
On the first day of 2026, hundreds of thousands of low-income Americans found themselves at the intersection of fiscal anxiety and medical necessity, as California and three other states quietly ended Medicaid coverage for GLP-1 weight loss drugs. The decision arrived even as the White House announced price reductions that would have made these same medications dramatically cheaper for state budgets — a collision of political timing, bureaucratic inertia, and the chronic human struggle with obesity. What unfolds now is a familiar tension in public health: the cost of treating a condition weighed against the far greater cost of leaving it untreated.
- Hundreds of thousands of low-income patients lost Medicaid coverage for GLP-1 weight loss drugs on January 1st, with no warning and no alternative plan beyond advice to diet and exercise.
- California projected $800 million in annual costs as justification — yet the Trump administration had already negotiated an 82% price reduction that would have brought monthly Medicaid costs down to $245, a figure the state declined to act on.
- Medical experts are sounding alarms: obesity is a chronic condition, weight regain after stopping treatment is nearly inevitable, and the long-term healthcare costs of untreated obesity will likely dwarf any short-term savings.
- States like Michigan, Rhode Island, and Wisconsin are moving toward similar cuts, reversing a wave of coverage expansion that had reached 16 states just months earlier.
- Patients now face a narrowing corridor — pay out of pocket, switch to a cheaper pill form not yet widely available, or stop treatment and absorb the health consequences that follow.
When 2026 began, hundreds of thousands of low-income Californians discovered their weight loss medications were no longer covered by Medi-Cal. California joined Pennsylvania, New Hampshire, and South Carolina in cutting Medicaid coverage for GLP-1 drugs like Wegovy and Zepbound when prescribed specifically for obesity — while continuing to cover the same medications for diabetes, heart disease, and kidney disease.
For families like that of Wilmer Cardenas in Santa Clara, the stakes were deeply personal. His husband had lost nearly 100 pounds over two years on GLP-1 injections covered by Medi-Cal. Because the prescription was tied to a diabetes diagnosis, they hoped coverage might continue — but the fragility of that distinction was not lost on them.
California's rationale was financial: state officials projected that covering GLP-1s for weight loss would cost nearly $800 million annually within four years. By 2024, Medi-Cal was already paying for more than 645,000 GLP-1 prescriptions. When the Trump administration's TrumpRx program announced it had negotiated Wegovy's monthly Medicaid cost down to $245 — from nearly $1,350 — California said it had no plans to reverse course. The decision had already been written into law.
Medical experts were blunt about the consequences. Researchers and clinicians described obesity as a chronic condition requiring indefinite treatment, much like hypertension or diabetes. Patients who stop the drugs typically regain the weight. California's official guidance — recommending diet, exercise, and counseling as alternatives — struck many physicians as disconnected from the clinical reality they face daily, where most patients have already exhausted those options before ever reaching a doctor's office.
The cuts landed against a backdrop of surging GLP-1 use nationwide: roughly one in eight American adults were taking these drugs by late 2025, and over half reported struggling to afford them. For low-income patients now losing Medicaid coverage, the options narrowed to paying out of pocket, hoping a cheaper pill formulation might help, or stopping treatment entirely — and absorbing the health costs that experts warn will follow.
At the start of 2026, hundreds of thousands of low-income Californians woke to find their weight loss medications no longer covered by the state's Medicaid program. The cuts came despite a White House initiative announced in November that promised to slash the price of these drugs by as much as 82 percent, making them far cheaper for taxpayers and state budgets alike. California joined Pennsylvania, New Hampshire, and South Carolina in eliminating Medicaid coverage for GLP-1 drugs like Wegovy and Zepbound when used specifically for weight loss, though the states continued to cover the same medications for diabetes, heart disease, and kidney disease.
Wilmer Cardenas of Santa Clara watched the change unfold with particular concern. His husband, Jeffer Jimenez, had lost roughly 100 pounds over two years using GLP-1 injections covered by Medi-Cal, California's Medicaid program. The transformation was dramatic. "Of course he tried eating well and everything, but now with the medications, it's better — a 100% change," Cardenas said. Jimenez's prescription was technically for diabetes, which meant the couple hoped to keep their coverage, but the underlying reality was clear: the drug had changed his life in ways diet and exercise alone never could.
California's decision rested on a stark financial projection. State officials calculated that covering GLP-1s for weight loss would cost nearly $800 million annually within four years if they did nothing. The state had covered these drugs since 2006, but their use exploded only recently. By 2024, Medi-Cal was paying for more than 645,000 GLP-1 prescriptions across all uses. The sheer volume, combined with the drugs' high price tag, forced a choice. When asked whether California would reconsider in light of the Trump administration's price cuts, a Department of Finance spokesperson said the state had no plans to reverse course. The decision was written into law.
Yet the price reductions announced through the White House's TrumpRx program were substantial. Wegovy's monthly cost would drop from nearly $1,350 to $350 for consumers, and Medicaid would pay just $245. Despite these numbers, states pressed ahead with their cuts, citing budget pressures that extended far beyond any single drug. Michigan, Rhode Island, and Wisconsin were considering or planning similar restrictions. A survey by the Kaiser Family Foundation found that interest in covering GLP-1s for obesity had peaked in October at 16 states; by January, that momentum had reversed.
Medical experts warned that the cuts would backfire. Diana Thiara, medical director of the University of California-San Francisco Weight Management Program, said the consequences would be "quite negative for our patients." The research was unambiguous: people typically regain weight after stopping the drugs. Kurt Hong, founding director of the Center for Clinical Nutrition at the Keck School of Medicine of the University of Southern California, explained that obesity is generally understood as a chronic condition requiring indefinite treatment, much like diabetes or hypertension. "Once they reach their target weight, a lot of people will try to see whether or not they can wean off," Hong said. "We do see a lot of patients — when they try to get off, unfortunately, then the weight comes back."
California's official response was to recommend that Medi-Cal members pursue "diet changes, increased activity or exercise, and counseling" instead. A state health official said this advice was meant to "encourage" members to take a "renewed, proactive, and medically supported approach." But Hong and others found this guidance disconnected from reality. By the time most patients reach a doctor, they have already failed at achieving results through diet and exercise alone. "We definitely want patients to do their part with the diet and exercise, but unfortunately, and from a practical standpoint, that itself frequently is not enough," Hong said.
The broader context made the timing particularly painful. A Kaiser Family Foundation poll released in November found that roughly one in eight American adults were now taking a GLP-1 drug for obesity, disease, or both—up six percentage points from May 2024. Over half of those users reported that the medications were difficult to afford. Many who had stopped treatment cited cost as the reason. Now, with Medicaid coverage gone, low-income patients faced a narrowing set of options: pay out of pocket, try the newly approved pill version of Wegovy (expected to cost around $149 monthly for the lowest dose), or stop treatment altogether and watch the weight return.
Catherine Ferguson, vice president of federal advocacy for the American Diabetes Association and its affiliated Obesity Association, noted the uncertainty hanging over the situation. It remained unclear how states would respond as more details about the Trump administration's pricing agreements emerged. "Many states are facing budgetary challenges, such as deficits, and are working to address the impacts of the changes to Medicaid and SNAP," Ferguson wrote. The White House did not respond to requests for comment on why states were proceeding with coverage cuts despite the price negotiations.
For patients like Jimenez, the path forward remained unclear. He could continue his injections if he could prove medical necessity for his diabetes rather than weight loss—a distinction that felt artificial to those living it. Others would have to choose between financial hardship and health consequences that experts said would likely cost the system far more in the long run.
Citas Notables
Of course he tried eating well and everything, but now with the medications, it's better — a 100% change.— Wilmer Cardenas, Santa Clara resident, describing his husband's weight loss on GLP-1 drugs
Once they reach their target weight, a lot of people will try to see whether or not they can wean off. We do see a lot of patients — when they try to get off, unfortunately, then the weight comes back.— Kurt Hong, founding director of the Center for Clinical Nutrition at Keck School of Medicine of USC
La Conversación del Hearth Otra perspectiva de la historia
Why would a state cut a drug that the federal government just negotiated down in price? That seems backwards.
Because states are operating under their own budget constraints, separate from federal negotiations. California was looking at $800 million a year in costs if they didn't act. The price cuts help, but they don't solve the underlying problem—these drugs are still expensive, and states are in crisis mode.
But wouldn't preventing weight regain actually save money down the line? Obesity leads to diabetes, heart disease, all the expensive stuff.
Absolutely. That's what the doctors are saying. But state budgets work on annual cycles. They need to cut now, not bet on savings that might materialize years from now. It's a short-term fix that creates long-term problems.
So what happens to someone like Jeffer Jimenez? He loses access?
Not necessarily. His prescription is technically for diabetes, not weight loss, so he might keep coverage. But that's a technicality. The real issue is that thousands of people who were on these drugs purely for weight loss now have to choose between paying hundreds of dollars a month or stopping treatment.
And when they stop?
The weight comes back. The doctors are clear on this. Obesity is chronic. You don't cure it and move on. You manage it, often indefinitely. Stopping the drug is like stopping insulin for a diabetic.
Is there any chance states will reverse course once they see the actual savings from the price cuts?
The state said no. California's decision is written into law. And other states are watching. Once you cut something, it's politically hard to restore it, even if the math changes.